Target intelligence / Profile preview

Envelope protein of tick-borne encephalitis virus (E protein (TBEV))

Target
E protein (TBEV)
Molecular classification
Viral fusion protein, Surface glycoprotein, Envelope protein
01

Overview

The envelope protein of tick-borne encephalitis virus (E protein, TBEV) is a structural glycoprotein and the principal surface component of the mature virion[1][4]. It forms antiparallel dimers that lie horizontally in the viral membrane, comprising four domains: the central β-barrel domain I, an elongated domain II containing the fusion loop required for membrane fusion, an immunoglobulin-like domain III thought to participate in host receptor binding, and a membrane-proximal stem-anchor region (domain IV)[1][2][3]. The E protein mediates multiple essential steps in the viral life cycle: attachment to host cells, receptor binding, pH-dependent membrane fusion during cell entry, and induction of virus-neutralizing antibodies[4]. It is also a major target for both vaccine and therapeutic antibody development, and a critical determinant of viral infectivity, host range, and neurovirulence[1][3][4].

Other names
E glycoprotein (TBEV)Tick-borne encephalitis virus envelope glycoprotein ETBEV E protein
02

Mechanism of action

Neutralizing antibodies block viral binding or prevent conformational changes required for membrane fusion; Inhibition of envelope protein function prevents viral entry into host cells

03

Biological functions

Mediates viral attachment to host cell surfaceFacilitates receptor bindingPromotes pH-dependent membrane fusion between viral and endosomal membranesInduces host immune (neutralizing antibody) responseInvolved in virus assembly and maturation
04

Disease associations

Infection (critical for tick-borne encephalitis virus infectivity and pathogenesis)Neurovirulence (associated with the ability of the virus to infect neural tissues)
05

Safety considerations

Antibody-dependent enhancement (ADE) of infection is a potential concern for flavivirus E proteinsPotential for immune escape mutationsCross-reactivity with other flaviviruses causing unintentional immune responses
06

Interacting drugs

Monoclonal antibodies (e.g., neutralizing antibody 19/1786)

1 more in the full profile.

07

Biomarkers

Presence of anti-E-protein antibodies as markers of exposure or vaccinationEnvelope (E) protein antigen in viral diagnostics

Beyond the preview

Go deeper on Envelope protein of tick-borne encephalitis virus (E protein (TBEV)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Envelope protein of tick-borne encephalitis virus (E protein (TBEV)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call